Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 26.43 billion. The enterprise value is 19.91 billion.
| Market Cap | 26.43B |
| Enterprise Value | 19.91B |
Important Dates
The next confirmed earnings date is Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.70 billion shares outstanding. The number of shares has increased by 11.63% in one year.
| Current Share Class | 1.43B |
| Shares Outstanding | 1.70B |
| Shares Change (YoY) | +11.63% |
| Shares Change (QoQ) | -0.45% |
| Owned by Insiders (%) | 19.89% |
| Owned by Institutions (%) | 31.15% |
| Float | 1.15B |
Valuation Ratios
The trailing PE ratio is 21.42 and the forward PE ratio is 65.75.
| PE Ratio | 21.42 |
| Forward PE | 65.75 |
| PS Ratio | 8.23 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | 160.26 |
| P/OCF Ratio | 100.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.34, with an EV/FCF ratio of 120.75.
| EV / Earnings | 18.77 |
| EV / Sales | 6.20 |
| EV / EBITDA | 21.34 |
| EV / EBIT | 24.48 |
| EV / FCF | 120.75 |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.29.
| Current Ratio | 4.21 |
| Quick Ratio | 3.87 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 2.76 |
| Debt / FCF | 15.63 |
| Interest Coverage | 12.49 |
Financial Efficiency
Return on equity (ROE) is 12.77% and return on invested capital (ROIC) is 33.79%.
| Return on Equity (ROE) | 12.77% |
| Return on Assets (ROA) | 4.28% |
| Return on Invested Capital (ROIC) | 33.79% |
| Return on Capital Employed (ROCE) | 7.80% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | 2.31M |
| Profits Per Employee | 764,309 |
| Employee Count | 1,388 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, InnoCare Pharma has paid 16.14 million in taxes.
| Income Tax | 16.14M |
| Effective Tax Rate | 1.50% |
Stock Price Statistics
The stock price has decreased by -13.06% in the last 52 weeks. The beta is 0.37, so InnoCare Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -13.06% |
| 50-Day Moving Average | 14.21 |
| 200-Day Moving Average | 13.12 |
| Relative Strength Index (RSI) | 40.86 |
| Average Volume (20 Days) | 7,838,068 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 3.21 billion and earned 1.06 billion in profits. Earnings per share was 0.58.
| Revenue | 3.21B |
| Gross Profit | 2.94B |
| Operating Income | 813.54M |
| Pretax Income | 1.08B |
| Net Income | 1.06B |
| EBITDA | 899.18M |
| EBIT | 813.54M |
| Earnings Per Share (EPS) | 0.58 |
Balance Sheet
The company has 9.11 billion in cash and 2.58 billion in debt, with a net cash position of 6.53 billion or 3.84 per share.
| Cash & Cash Equivalents | 9.11B |
| Total Debt | 2.58B |
| Net Cash | 6.53B |
| Net Cash Per Share | 3.84 |
| Equity (Book Value) | 8.87B |
| Book Value Per Share | 5.04 |
| Working Capital | 8.10B |
Cash Flow
In the last 12 months, operating cash flow was 262.29 million and capital expenditures -97.38 million, giving a free cash flow of 164.90 million.
| Operating Cash Flow | 262.29M |
| Capital Expenditures | -97.38M |
| Depreciation & Amortization | 87.17M |
| Net Borrowing | 777.80M |
| Free Cash Flow | 164.90M |
| FCF Per Share | 0.10 |
Margins
Gross margin is 91.61%, with operating and profit margins of 25.34% and 33.05%.
| Gross Margin | 91.61% |
| Operating Margin | 25.34% |
| Pretax Margin | 33.57% |
| Profit Margin | 33.05% |
| EBITDA Margin | 28.01% |
| EBIT Margin | 25.34% |
| FCF Margin | 5.05% |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 3.93% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.63% |
| Shareholder Yield | -11.63% |
| Earnings Yield | 4.01% |
| FCF Yield | 0.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for InnoCare Pharma is 19.01, which is 52.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 19.01 |
| Price Target Difference | 52.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 16.55% |
| EPS Growth Forecast (3Y) | -3.90% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | 6 |